Investor Relations

Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix Powerlink System is an endoluminal stent graft (ELG) for treating Abdominal Aortic Aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the thirteenth leading cause of death in the U.S.

2006 Annual Report

Addressing a significant medical problem. Approximately 1.7 million Americans have AAA, and the incidence of the condition increases with age.

Superior, patented design. The technology is a minimally invasive device, allowing for greater patient comfort and quicker recovery compared to invasive surgical alternatives. Covered by 17 U.S. patents with 361 allowed claims, the technology is designed to overcome the significant shortcomings of first-generation ELGs.

Compelling clinical data. There is a significant reduction in blood loss, operative time, Intensive Care Unit (ICU) utilization and hospital length of stay for Powerlink patients when compared with traditional open surgical repair for AAA. Also, on-going clinical study results show there is a lower mortality for Powerlink patients than in open surgical repair patients.

Seasoned management team. The executive management team has a record of building shareholder value with over 120 years of combined medical device experience and a strong record of success with medical products.

Recent News

April 10, 2008
ENDOLOGIX TO HOLD 2008 FIRST QUARTER FINANCIAL RESULTS CONFERENCE CALL ON APRIL 24

April 8, 2008
FIRST COMMERCIAL PROCEDURES PERFORMED IN JAPAN WITH ENDOLOGIX POWERLINK SYSTEM

February 21, 2008
ENDOLOGIX REPORTS FOURTH QUARTER RESULTS

February 11, 2008
ENDOLOGIX LAUNCHES THE POWERLINK SYSTEM IN JAPAN